Grifols

GRFS

Barcelona, Spain· Est. 1909

grifols.com

Is this your company? Claim your profile to update info and connect with investors.

Claim profile

GRFS · Stock Price

USD 8.06+0.96 (+13.52%)

Market Cap: $5.5B

Historical price data

Market Cap: $5.5BPipeline: 102 drugs (36 Phase 3)Patents: 20Founded: 1909Employees: 24,000+ (global estimate)HQ: Barcelona, Spain

Sector Ranking#79 in Biologics / Biosimilars #45 in Diagnostics & Precision Medicine

Overview

Grifols is a century-old global leader in plasma-derived medicines and diagnostics, operating across four core divisions: Biopharma, Diagnostics, Bio Supplies, and Hospital Healthcare Solutions. Its mission to improve health is powered by deep plasma science expertise, a robust manufacturing footprint, and significant industry recognition, including repeated honors from TIME and Forbes. The company's strategy focuses on vertical integration in plasma, geographic expansion, and scientific innovation, including exploring new therapeutic areas like neurology through its CHRONOS-PD platform.

ImmunologyHematologyHepatologyIntensive CarePulmonologyNeurologyInfectious Diseases

Technology Platform

Proprietary 'Plasma Powerhouse' platform encompassing vertically integrated plasma collection, advanced fractionation and purification technologies, and complementary diagnostic systems for transfusion medicine.

Pipeline

102

102 drugs in pipeline36 in Phase 3

Drug	Indication	Stage
Tetanus Immune Globulin (Human) + Diphtheria-Tetanus Toxoids...	Tetanus	Approved
Alphanate SD/HT	Von Willebrand Disease	Approved
(100 ml of Albumin 25%)	Hypotension During Dialysis	Approved
IVIG	Myasthenia Gravid	Approved
FVIII + Emicizumab	Hemophilia A	Approved

FDA Approved Drugs

SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINERANDAMay 25, 2017

Opportunities

The global plasma-derived therapies market is growing and supply-constrained, favoring vertically integrated leaders like Grifols.

Geographic expansion into underpenetrated emerging markets and the exploration of new indications (e.g., neurology via CHRONOS-PD) provide long-term growth avenues.

The planned U.S.

Biopharma IPO could unlock significant value and strengthen the balance sheet.

Risk Factors

High financial leverage pressures cash flow and creates vulnerability to interest rate changes.

The business is entirely dependent on costly human plasma collection, which is susceptible to donor volatility and regulatory changes.

Competitive intensity and the long-term threat of recombinant or gene therapy alternatives to some plasma products pose ongoing challenges.

Competitive Landscape

Grifols competes in an oligopolistic global plasma fractionation market primarily against Takeda and CSL Behring. Competition is based on scale, vertical integration (plasma collection network), product portfolio breadth, and manufacturing efficiency. Grifols differentiates through its integrated Biopharma+Diagnostics model and strength in specific therapeutic areas like alpha-1 antitrypsin deficiency.